Literature DB >> 18626657

Occult disseminated tumor cells in lymph nodes of patients with gastric carcinoma. A critical appraisal of assessment and relevance.

Peter Scheunemann1, Nikolas H Stoecklein, Kai Hermann, Alexander Rehders, Claus F Eisenberger, Wolfram T Knoefel, Stefan B Hosch.   

Abstract

BACKGROUND AND AIMS: In gastric cancer, regional lymph node metastasis verified by histopathological examination is the most important prognostic factor after complete surgical tumor resection (R0). However, the prognostic value of immunohistochemically identifiable disseminated tumor cells in lymph nodes without histopathological tumor burden in patients with gastric cancer is still controversially discussed. The aim of the study was to assess the frequency and prognostic impact of minimal tumor cell spread to lymph nodes in these patients. PATIENTS-
METHODS: One hundred sixty lymph nodes judged as "tumor free" on routine histopathology obtained from 58 patients with gastric adenocarcinoma were analyzed immunohistochemically using the monoclonal anti-EpCAM antibody Ber-EP4 for occult disseminated tumor cells.
RESULTS: Tumor cells in lymph nodes were detected in 62 (38.8%) of the 160 "tumor-free" lymph nodes obtained from 39 (67.2%) patients. Multivariate Cox regression analysis confirmed the presence of disseminated tumor cells in "tumor-free" lymph nodes as an independent prognostic factor for both a significantly reduced relapse-free survival (p = 0.008) and overall survival (p = 0.009).
CONCLUSIONS: The frequent occurrence and prognostic impact of minimal disseminated tumor cells in lymph nodes of patients with gastric carcinoma support the need for a refined staging system of excised lymph nodes, which should include immunohistochemical examination.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18626657     DOI: 10.1007/s00423-008-0369-4

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  50 in total

1.  Lymph node micrometastases in patients with adenocarcinoma of the esophagogastric junction.

Authors:  L Bonavina; S Ferrero; V Midolo; R Buffa; B Cesana; A Peracchia
Journal:  J Gastrointest Surg       Date:  1999 Sep-Oct       Impact factor: 3.452

2.  Improved tumor staging in colorectal cancer.

Authors:  A Lindblom
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

3.  Occurrence and prognostic implications of micrometastases in lymph nodes from patients with submucosal gastric carcinoma.

Authors:  Hong-Jo Choi; Yun-Ki Kim; Young-Hoon Kim; Sang-Soon Kim; Sook-Hee Hong
Journal:  Ann Surg Oncol       Date:  2002 Jan-Feb       Impact factor: 5.344

Review 4.  Adjuvant therapy in gastric cancer.

Authors:  Lionel Lim; Michael Michael; G Bruce Mann; Trevor Leong
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

5.  Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow.

Authors:  A Zippelius; P Kufer; G Honold; M W Köllermann; R Oberneder; G Schlimok; G Riethmüller; K Pantel
Journal:  J Clin Oncol       Date:  1997-07       Impact factor: 44.544

6.  Clinicopathological value of immunohistochemical detection of occult involvement in pT3N0 gastric cancer.

Authors:  Jianhui Cai; Masahide Ikeguchi; Michio Maeta; Nobuaki Kaibara; Takashi Sakatani
Journal:  Gastric Cancer       Date:  1999-08       Impact factor: 7.370

7.  Lymph node micrometastases in early gastric cancer and their impact on prognosis.

Authors:  Paolo Morgagni; Luca Saragoni; Emanuela Scarpi; Pier Sante Zattini; Alberto Zaccaroni; Diana Morgagni; Francesca Bazzocchi
Journal:  World J Surg       Date:  2003-04-28       Impact factor: 3.352

8.  Early lymphatic tumor cell dissemination in pancreatic cancer: frequency and prognostic significance.

Authors:  S B Hosch; W T Knoefel; S Metz; N Stoecklein; A Niendorf; C E Broelsch; J R Izbicki
Journal:  Pancreas       Date:  1997-08       Impact factor: 3.327

9.  Clinical significance of occult micrometastasis lymph nodes from patients with early gastric cancer who died of recurrence.

Authors:  Y Maehara; T Oshiro; K Endo; H Baba; S Oda; Y Ichiyoshi; S Kohnoe; K Sugimachi
Journal:  Surgery       Date:  1996-04       Impact factor: 3.982

10.  Prognostic significance of the number of positive lymph nodes in gastric carcinoma.

Authors:  Y Adachi; T Kamakura; M Mori; H Baba; Y Maehara; K Sugimachi
Journal:  Br J Surg       Date:  1994-03       Impact factor: 6.939

View more
  9 in total

1.  The unbearable lightness of understanding clinical influence of lymph node micrometastasis.

Authors:  Ozgür Akgül; Mesut Tez; Mahmut Koç
Journal:  Langenbecks Arch Surg       Date:  2008-10-15       Impact factor: 3.445

2.  Monoclonal antibody CAM5.2 can detect the cytokeratin 8, not cytokeratin 18. Comment on: "Occult disseminated tumor cells in lymph nodes of patients with gastric carcinoma. A critical appraisal of assessment and relevance. Langenbecks Arch Surg. 2009 Jan; 394(1): 105-113.".

Authors:  Chung-Chin Yao; Szu-Wen Tseng; Chih-Ping Han
Journal:  Langenbecks Arch Surg       Date:  2010-03       Impact factor: 3.445

3.  Gastric cancer: Where is the place for the surgeon, the oncologist and the endoscopist today?

Authors:  Markus Menges
Journal:  World J Gastrointest Oncol       Date:  2011-01-15

4.  The prognostic significance of isolated tumor cells in the lymph nodes of gastric cancer patients.

Authors:  Takeo Fukagawa; Mitsuru Sasako; Seiji Ito; Hayao Nakanishi; Hisae Iinuma; Shoji Natsugoe; Hitoshi Katai; Tadakazu Shimoda
Journal:  Gastric Cancer       Date:  2010-09-05       Impact factor: 7.370

5.  Tumor margin detection using quantitative NIRF molecular imaging targeting EpCAM validated by far red gene reporter iRFP.

Authors:  Banghe Zhu; Grace Wu; Holly Robinson; Nathaniel Wilganowski; Mary A Hall; Sukhen C Ghosh; Kenneth L Pinkston; Ali Azhdarinia; Barrett R Harvey; Eva M Sevick-Muraca
Journal:  Mol Imaging Biol       Date:  2013-10       Impact factor: 3.488

6.  Tumor antigen cross-presentation and the dendritic cell: where it all begins?

Authors:  Alison M McDonnell; Bruce W S Robinson; Andrew J Currie
Journal:  Clin Dev Immunol       Date:  2010-10-13

7.  Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation.

Authors:  Alison M McDonnell; Andrew J Currie; Matthew Brown; Kasia Kania; Ben Wylie; Amanda Cleaver; Richard Lake; Bruce W S Robinson
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

8.  Significant co-expression of putative cancer stem cell markers, EpCAM and CD166, correlates with tumor stage and invasive behavior in colorectal cancer.

Authors:  Elham Kalantari; Tahereh Taheri; Saba Fata; Maryam Abolhasani; Mitra Mehrazma; Zahra Madjd; Mojgan Asgari
Journal:  World J Surg Oncol       Date:  2022-01-11       Impact factor: 2.754

9.  Impact of multisection and immunohistochemistry in lymph node staging of Gastric Carcinoma - Case series.

Authors:  Fernando A V Santos; Ana P Drummond-Lage; Alberto J A Wainstein; Marco A Dias-Filho; Paulo R Savassi-Rocha; Tulio P Navarro
Journal:  Sci Rep       Date:  2020-02-24       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.